Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Immunotherapy in Ovarian and Colon Cancer, Lymphoma, GBM Brain Tumors and Other Cancers

Immunotherapy in Ovarian and Colon Cancer, Lymphoma, GBM Brain Tumors and Other Cancers

Immunotherapy 2.0 is our continuing topic;

A Chance to Slow Ovarian Cancer with Immunotherapy

Worldwide, in 2012, 239000 women developed ovarian cancer. Our 2014 statistics place it as the 7th most common female cancer nationally.

Without disease-specific early symptoms, ovarian cancer is often diagnosed late. Despite good surgical and chemotherapy responses, recurrence requires particular vigilance.

A 2015 study suggested nivolumab may help after recurrence following standard platinum chemotherapy. Of 20 women, 3 had tumor regression and 6 stopped progressing. Complete remission occurred in 2, including one with relatively chemotherapy-resistant clear-cell carcinoma.

These findings encourage research on integrating immunotherapy optimally. Studies combining nivolumab and other immune drugs in recurrent ovarian cancer continue.

The Situation in Lymphoma

Hodgkin lymphoma (HL), a lymphatic cancer generally sensitive to PD-1 inhibitors, is uncommon compared with organ cancers and more frequent in men and young adults.

Classic HL is the commonest form (%95). Treatments developed over forty years have improved survival; most respond well to chemotherapy, with five-year survival of %86. However, about %20 to %30 never respond or relapse. More sensitive treatments, such as high-dose chemotherapy followed by autologous stem cell transplantation (ASCT), are needed. Recurrence after ASCT prompts new chemotherapy/targeted regimens, such as brentuximab vedotin.

In May 2016, nivolumab received FDA approval for classic HL . Genetically altered advanced Hodgkin cells are called Reed-stenberg cells. These changes arise through increased PD-L1 and PD-L2, checkpoint molecules suppressing immune responses. This suggests PD-1 inhibitors for HL.

Another study found pembrolizumab effective in young refractory or relapsed HL patients. Among 31, 20 entered remission and 5 complete remission. Nearly all tumors regressed, with responses mostly exceeding 24 weeks. In April 2016, pembrolizumab received FDA approval for recurrent classic HL. Its effects in multiple myeloma and other blood cancers are also tested.

New Clues for Patient Selection

As immunotherapy expands, a difficult biological puzzle remains:

  • Why do checkpoint inhibitors work very well in some cancers and not at all in others?
  • Why do some patients with the same cancer respond while others do not?

Future immunotherapy research will focus on these questions. With high costs and fewer but sometimes serious side effects versus chemotherapy, identifying beneficiaries is essential. Although no certain prediction exists, physicians can often estimate benefit from individual characteristics and cancer biology. Scientists are studying biomarkers predicting response. High PD-L1 is expected to indicate response to PD-1 blockade, while absent PD-L1 suggests no benefit. However, the relationship between PD-L1 and PD-1 response is unclear in ovarian cancer and melanoma. Trials show some lung cancers respond to PD-1 inhibitors despite low PD-L1.

A major problem is lack of standardized PD-1 and PD-L1 analyses. Optimal assays and reagents, and whether PD-L1 originates solely from cancer cells or also surrounding tissue, remain unclear. Cutoffs vary with assays and methods. These issues must be resolved before markers are considered reliable clinical tools.

Researchers also investigate why tumors regressing with PD-1 inhibitors regrow. A melanoma study suggested mutations in immune-related genes may cause resistance to PD-1 blockade.

Checkpoint Inhibitors Work Better with Genomic Instability (Microsatellite Instability = Hypermutation)

Biomarker research for checkpoint inhibitors and other immunotherapies is evolving, with several important clues.

First, tumors with many mutations appear more sensitive. They may produce more abnormal proteins (antigens) recognized as foreign by immunity.

Proposed mutation-burden tests include sequencing the entire cancer gene and counting mutations, or sequencing selected gene panels and measuring their mutation rate.

Highly mutated, or hypermutated, cancers prominently include those caused by tobacco —lung, head-and-neck and bladder cancers—or UV exposure, such as melanoma and head-and-neck cancers. It is therefore unsurprising these respond particularly well to checkpoint inhibition in trials.

microsatellite formation lynch syndrome colon cancer mmr msi 1024x393

Microsatellite formation: DNA is copied by pairing each nucleotide, such as adenine (A) with thymine (T) and cytosine (C) with guanine (G). Pairing 3 billion nucleotides can introduce errors such as mismatches, normally corrected by DNA repair genes. Failure is called “mismatch repair (MMR) defect.” Unmatched sequences called “microsatellites” repeat and accumulate, causing genomic instability.

Cancers in patients with a genetic abnormality called DNA missmatch repair (MMR) deficiency, reducing repair ability, were found to contain many mutations. Earlier research suggests that in DNA MMR deficiency, patients with colorectal or brain cancers benefit from checkpoint inhibitors. They are less effective in the same cancers without deficiency.

These results are exciting but preliminary. Ongoing studies may identify tests focusing checkpoint treatment on those benefiting most.

MMR defects occur in %15 of colorectal cancers and also uterine, prostate and ovarian cancers. A 2015 trial demonstrated an association between defective repair and checkpoint response. Of 10 colorectal patients with defective repair, 4 responded to the PD-1 inhibitor pembrolizumab. None of 18 without defects responded. Deficient tumors averaged 1.782 mutations versus 73 in others.

More research is needed, but these early findings suggest testing MMR defects or tumor mutation numbers, called mutational burden, may identify beneficiaries of PD-1 / PD-L1 immunotherapy.

Childhood Brain Tumors

In 2016, researchers reported another mismatch-repair-related cancer sensitive to checkpoint inhibition: the difficult-to-treat pediatric glioblastoma multiforme (GBM). Most children relapse despite surgery, radiotherapy and chemotherapy. With median survival of 6 months, recurrent GBM urgently needs effective treatments. The study focused on biallelic MMR deficiency , a rare childhood predisposition syndrome. All affected children develop brain, blood or gastrointestinal cancers within their first twenty years, most commonly brain cancer. Researchers analyzed mutation rates in 37 tumors from different tissues. All high-grade tumors had many mutations (average 1.589), with deficient GBMs highest (average 17.740). These were the most mutated among all pediatric and adult brain cancers. Based on prior links between mutations and response, researchers expected good results. Two siblings with recurrent biallelic MMR-deficient GBM received nivolumab. After 12 weeks, tumors shrank and health improved. After 9 and 5 months respectively, the sister and brother returned to school and normal activities. Authors called this the first report of sustained checkpoint responses in recurrent GBM.

Encouragingly, most children with recurrent GBM deteriorate within 1 or 2 months and die within 3 to 6 months.

Findings also inform adult GBM and other deficient cancers, highlighting genetic testing for checkpoint treatment selection.

Another rare cancer sensitive to PD-1 inhibitors is Merkel cell skin cancer. Advanced disease is aggressive and worsens within 3 months of initial chemotherapy. Like other skin cancers it arises with UV exposure; %80 are also associated with Merkel cell polyomavirus infection.

Sources

Harold J. Burstein, Lada Krilov, Jeanny B. Aragon-Ching et. al.,
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
J Clin Oncol 35. 2017 by American Society of Clinical Oncology

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Immunotherapy in Ovarian and Colon Cancer, Lymphoma, GBM Brain Tumors and Other Cancers

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy